Minivelle (estradiol transdermal system) Patches, Delivers 0.075 mg/day, 8 count boxes, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. By: Noven Therapeutics, LLC. Miami, Florida 33186 --- NDC 68968-6675-8

Recall Insight

This FDA Drug action (record #D-1210-2018) was formally reported on October 3, 2018, with the manufacturer initiating the action on September 7, 2018. It is classified under Moderate severity (Class II), with a current status of Terminated. Noven Pharmaceuticals, Inc. is listed as the recalling firm, operating out of Miami, FL. Federal records indicate 74908 boxes of 8 patches units are affected, a scale large enough to require multi-state distribution tracking.

The documented reason for this recall is: Defective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches. Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

To put this record in context, PlainRecalls indexes 83,949 recalls across the FDA, CPSC, NHTSA and USDA FSIS going back to 1995. Within the same product category, the database holds 6 closely related recalls, of which 5 were also issued by FDA Drug. That clustering is a signal — repeated actions in a narrow category often indicate a systemic quality-control issue, a supplier-wide contamination, or a design defect that has propagated across product lines. This recall is roughly 8 years old; older recalls can remain relevant because many units enter resale, rental, and secondary-market channels where the original warning never reaches the end user. Always cross-check the recall number against the official agency page before relying on any summary.